Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wagner, Sebastian
NCT-PMO-1603, NCT03127215 / 2017-001755-31: Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors	Completed	2	102	Europe	Olaparib, Physician's choice, Trabectedin	National Center for Tumor Diseases, Heidelberg, AstraZeneca, PharmaMar, German Cancer Research Center	Cancers With DNA Repair-Deficiency	12/23	12/23
MIROVA, NCT04274426 / 2018-004207-39: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer	Active, not recruiting	2	136	Europe	Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine	AGO Research GmbH, ImmunoGen, Inc.	Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma	12/25	12/26
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology	Completed	N/A	499	Europe		iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG	Advanced Solid Tumors or Hematologic Malignancies	06/23	06/23